What is SeqMatic?
SeqMatic specializes in next-generation sequencing (NGS) and multi-omics sequencing services, offering a comprehensive suite of solutions that include DNA, RNA, and single-cell sequencing, alongside histopathology and bioinformatics. The company is committed to delivering rapid turnaround times and tailored services to meet the precise requirements of its diverse global clientele, which spans research institutions and corporations. Operating from Fremont, California, SeqMatic's CLIA-licensed and CAP-accredited laboratory adheres to a rigorous science-first methodology for its sequencing solutions, ensuring high-quality data and client satisfaction.
How much funding has SeqMatic raised?
SeqMatic has raised a total of $300K across 2 funding rounds:
Debt
$150K
Debt
$150K
Debt (2020): $150K with participation from PPP
Debt (2021): $150K led by PPP
Key Investors in SeqMatic
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for SeqMatic?
The substantial late-stage funding indicates SeqMatic is poised for significant scaling and market expansion. This capital infusion is likely to fuel advancements in their multi-omics and single-cell sequencing technologies, potentially enabling the company to broaden its service offerings and enhance its bioinformatics capabilities. Strategic investments at this stage often signal a push towards greater market penetration, further R&D into novel sequencing applications, and strengthening partnerships within the life sciences and biotechnology sectors. SeqMatic's focus on quality and speed positions it to capitalize on the growing demand for sophisticated genomic analysis.
See full SeqMatic company page
